Free shipping on all orders over $ 500

Toripalimab

Cat. No. M24853
Toripalimab Structure
Size Price Availability
5mg USD 280  USD280 4-7 Days
10mg USD 450  USD450 4-7 Days
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma.

Chemical Information
CAS Number 1924598-82-2
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Zi-Xian Wang, et al. Cancer Cell. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

[2] Lin Zhang, et al. Front Immunol. Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China

[3] Huabin Hu, et al. Lancet Gastroenterol Hepatol. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial

[4] Hai-Qiang Mai, et al. Nat Med. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

[5] Bixia Tang, et al. Expert Opin Biol Ther. Toripalimab for the treatment of melanoma

Related PD-1/PD-L1 Products
Rosnilimab

Rosnilimab is a novel PD-1 checkpoint agonist antibody that reduces overactive T cell inflammation. Rosnilimab optimizes PD-1+ T cell inhibitory signaling by enabling tight immune synapse formation. Rosnilimab restores immune balance bringing T cell composition to a less activated state.

Recombinant Anti-Mouse PD1 mAb

Recombinant Anti-Mouse PD1 mAb is a recombinant monoclonal antibody against the mouse PD1 protein, with the antibody isoform Mouse lgG1/lambda. the antibody efficiently binds to the mPD1 protein on the cell surface and significantly inhibits tumor growth in a mouse tumor model transplanted with MC38 cells. the antibody is used to detect the presence of the mouse PD1 protein on the cell surface of the cell. the antibody is used to detect the presence of the mouse PD1 protein on the cell surface of the cell.

Erfonrilimab

Erfonrilimab is a humanized single-domain bispecific antibody-Fc fusion protein (VH-VH-h-CH2-CH3 dimer) targeting the immune checkpoints PD-L1 and CTLA-4.

Benmelstobart

Benmelstobart is an anti-PD-L1 humanized IgG1ҡ monoclonal antibody that can be used for tumor-related studies.

Human PD-L1 inhibitor II

Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.

  Catalog
Abmole Inhibitor Catalog




Keywords: Toripalimab supplier, PD-1/PD-L1, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.